Mostrar o rexistro simple do ítem

dc.contributor.authorRubio, M.J.
dc.contributor.authorLecumberri, M.J.
dc.contributor.authorVarela Ferreiro, Silvia 
dc.contributor.authorAlarcón, J.
dc.contributor.authorOrtega, M.E.
dc.contributor.authorGaba, L.
dc.contributor.authorEspinós, J.
dc.contributor.authorCalzas, J.
dc.contributor.authorBarretina, P.
dc.contributor.authorRuiz, I.
dc.contributor.authorMarquina, G.
dc.contributor.authorSantaballa, A.
dc.date.accessioned2022-05-23T08:38:18Z
dc.date.available2022-05-23T08:38:18Z
dc.date.issued2020
dc.identifier.issn2352-5789
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pubmed/32566719es
dc.identifier.urihttp://hdl.handle.net/20.500.11940/16799
dc.description.abstractObjective: We assessed trabectedin in patients with advanced uterine leiomyosarcoma (uLMS) in real-life clinical practice given according to the marketing authorization. Methods: Thirty-six women from 11 tertiary hospitals across Spain who received trabectedin after anthracycline-containing regimen/s were retrospectively analyzed. The primary endpoint was progression-free survival (PFS). Results: Median PFS and overall survival (OS) since starting trabectedin treatment were 5.4 (95%CI: 3.5-7.3) and 18.5 months (95%CI: 11.5-25.6), respectively. Median OS was significantly higher (P = 0.028) in patients receiving trabectedin in </= 2nd line (25.3 months) than in >/= 3rd (15.1 months) and with ECOG performance status </= 1 at trabectedin start (19.8 months) than ECOG 2-3 (6.0 months, P = 0.013). When calculating OS since diagnosis, patients had longer OS with localized disease at diagnosis (87.4 months) vs. locally advanced (30.0 months) or metastatic (44.0 months, P = 0.041); and patients who received adjuvant therapy (87.4 months) compared with those who did not (30.0 months, P = 0.003), especially when receiving radiochemotherapy (106.7 months, P = 0.027). One patient (2.8%) had a complete response (CR) and nine patients (25.0%) achieved a partial response (PR) for an objective response rate of 27.8% with median response duration of 11 months (range: 4-93). Eighteen patients (50.0%) had disease stabilization for a disease control rate (DCR) of 77.8%. More patients receiving trabectedin in 1st-line of advanced disease achieved CR (16.7%) and PR (50.0%) than those in >/= 2nd line/s (0.0% and 20.0%), whereas the DCR was similar across treatment lines. Reversible neutropenia was the most common grade 3/4 laboratory abnormality (19.4%). Conclusions: Trabectedin confers clinical benefit in patients with recurrent/metastatic uLMS, given after failure to an anthracycline-based regimen being comparable to those reported in clinical trials and with a manageable safety profile.en
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.titleEfficacy and safety of trabectedin in metastatic uterine leiomyosarcoma: A retrospective multicenter study of the Spanish ovarian cancer research group (GEICO)en
dc.typeJournal Articlees
dc.authorsophosRubio, M.J.;Lecumberri, M.J.;Varela, S.;Alarcón, J.;Ortega, M.E.;Gaba, L.;Espinós, J.;Calzas, J.;Barretina, P.;Ruiz, I.;Marquina, G.;Santaballa, A.
dc.identifier.doi10.1016/j.gore.2020.100594
dc.identifier.pmid32566719
dc.identifier.sophos42921
dc.journal.titleGYNECOL ONCOLOGY REPORTSes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Lugo, Cervo e Monforte de lemos - Complexo Hospitalario Universitario Lucus Augusti::Oncoloxía médicaes
dc.page.final100594es
dc.rights.accessRightsopenAccess
dc.subject.keywordHULAes
dc.typefidesArtículo Originales
dc.typesophosArtículo Originales
dc.volume.number33.es


Ficheiros no ítem

Este ítem aparece na(s) seguinte(s) colección(s)

Mostrar o rexistro simple do ítem

Attribution-NonCommercial-NoDerivatives 4.0 International
A non ser que se indique outra cousa, a licenza do ítem descríbese comoAttribution-NonCommercial-NoDerivatives 4.0 International